ClinicalTrials.govpublic full text
Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years
secondary hyperparathyroidism, chronic kidney disease stage v, cardiac morbidity, secondary hyperparathyroidism (shpt), paricalcitol, chronic kidney disease stage 5 (ckd stage 5), observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 861372
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.